drugset / Trial / NCT05926232

Expanded Access for Repotrectinib

NCT05926232 ↗

Expanded access Available Bristol-Myers Squibb

Summary

This is an expanded access designed to provide access to Repotrectinib for eligible participants.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Background Repotrectinib Small molecule — —

Indications

No indication recorded.